Wednesday 28th November 2012
|Text too small?|
A2 Corp, which markets milk products with a protein variant claimed to have health benefits, had its shares halted from trading pending a statement.
The Sydney-based company, whose shares have more than doubled in the past 12 months, said last week it is in talks with the NZX about shifting its listing to the main board from the NZAX, a market for smaller companies and start-ups.
The shares traded at 67 cents yesterday, valuing the company at $399 million.
"A move to the NZX main board may provide greater liquidity and increase access to capital," managing director Geoffrey Babidge said last week.
Last month, the company completed a six-month strategic review and has embarked on plans to take control of its New Zealand marketing and accelerate its global expansion.
No comments yet
A2 Corp's Babidge, Mair take advantage of soaring price to sell 6M shares
A2 shares touch record-high as investors buy into growth story
A2 FY profit slips on cost of setting up UK joint venture, sales jump 51 percent as Australian shines
A2 first-half profit dented by UK joint venture, affirms annual earnings target of $11.2M
A2 to raise $20M in placement, big shareholders sell down
A2 Corp mulls capital structure in face of growth opportunities
A2 in talks with NZX about shifting to main board
A2 Corp to take control of NZ marketing; enter North America, Europe
A2 Corp talks up Chinese infant formula market potential
A2 more than doubles FY profit as Australian sales surge